OLFML2A and central nervous system cancer: The knockdown of OLFML2A in glioma cells inhibits the Wnt/β-catenin signaling pathway, which leads to upregulation of amyloid precursor protein (APP) expression and a decrease in the degree of stable β-catenin, resulting in having reduced MYC, CD44, and CSKN2A2 expression, thereby inhibiting cell proliferation and promoting apoptosis [21, 22].